What does this research mean for the field?

Tralokinumab treatment improves rash and itch severity in patients with moderate-to-severe atopic dermatitis over 72 weeks, with varying effectiveness based on baseline severity. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

February 19, 2026Open Access

Seventy‐Two‐Week Real‐World Outcomes of Tralokinumab Treatment for Moderate‐To‐Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity

Key Points

Evaluate the long-term effectiveness of tralokinumab treatment for moderate-to-severe atopic dermatitis stratified by baseline rash and itch severity.
Conducted a prospective study with 167 Japanese patients with moderate-to-severe atopic dermatitis.
Patients received tralokinumab treatment every two weeks for 72 weeks.
Assessed eczema area and severity index, investigator's global assessment, and peak pruritus numerical rating scale at multiple time points.
Data were analyzed based on four severity groups defined by baseline assessment scores.
Mean eczema area and severity index and peak pruritus numerical rating scale decreased in all patient groups through week 72.
The highest rates of achieving investigator's global assessment of 0/1 and complete resolution on the eczema area and severity index were noted in the group with moderate rash and high itch severity.
Only 10% achieved investigator's global assessment of 0/1 in the group with severe rash and low itch severity.

Abstract

ABSTRACT An anti–interleukin‐13 antibody tralokinumab is effective for atopic dermatitis (AD). However, there are no real‐world studies on its long‐term outcomes in patients stratified by rash and itch severity. To evaluate the effectiveness of 72‐week tralokinumab treatment in 4 groups of AD patients, stratified by baseline investigator's global assessment (IGA) and peak pruritus numerical rating scale (PP‐NRS), we conducted a prospective study of 167 Japanese patients with moderate‐to‐severe AD from October 2023 to October 2025. Patients received tralokinumab every two weeks. Eczema area and severity index (EASI), IGA, and PP‐NRS were assessed at weeks 0, 4, 12, 16, 24, 36, 48, 60, and 72. Data were analyzed separately in 4 groups; IGA 3/PP‐NRS < 7, IGA 3/PP‐NRS ≥ 7, IGA 4/PP‐NRS < 7, and IGA 4/PP‐NRS ≥ 7. Mean EASI and PP‐NRS decreased in all groups through week 72. The rates achieving IGA 0/1, EASI 100, and PP‐NRS ≥ 4‐point reduction were highest in the group with IGA 3/PP‐NRS ≥ 7 (53.6%, 17.9%, and 92.0%) while lowest in that with IGA 4/PP‐NRS < 7 (10.0%, 0%, and 22.2%). Tralokinumab improved rash and itch throughout 72 weeks across all groups stratified by rash and itch severity.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Yoneyama et al. (Mon,) studied this question.

synapsesocial.com/papers/6996a7ffecb39a600b3ee3c2 https://doi.org/https://doi.org/10.1111/1346-8138.70187

Bookmark

View Full Paper